Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The SURPASS-2 trial showing tirzepatide achieving significantly greater HbA1c reduction and weight loss than semaglutide in T2DM patients, and the SURMOUNT trials showing up to 22% average body weight reduction in obese patients, have established tirzepatide as the clinical performance leader in the class
2004;97(2):c41-c48
DOI: 10.1038/45230
For functional factors supported by sufficient human evidence, stratified application can be made according to their primary effects
Enzymology of H2S biogenesis, decay and signaling
US$ 28.89
US$ 23.39
US$ 27.12
US$ 28.42
